Țară: Statele Unite ale Americii
Limbă: engleză
Sursă: NLM (National Library of Medicine)
FEBUXOSTAT (UNII: 101V0R1N2E) (FEBUXOSTAT - UNII:101V0R1N2E)
Macleods Pharmaceuticals Limited
ORAL
PRESCRIPTION DRUG
Febuxostat is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. Limitations of Use: Febuxostat is not recommended for the treatment of asymptomatic hyperuricemia. Febuxostat is contraindicated in patients being treated with azathioprine or mercaptopurine [see Drug Interactions (7)]. Risk Summary Limited available data with febuxostat use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. No adverse developmental effects were observed in embryo-fetal development studies with oral administration of febuxostat to pregnant rats and rabbits during organogenesis at doses that produced maternal exposures up to 40 and 51 times, respectively, the exposure at the maximum recommended human dose (MRHD). No adverse development
Febuxostat 40 mg tablets are green, biconvex, round, film- coated tablets debossed with "M 87" on one side and plain on the other side and supplied as: NDC Number Size 33342-274-07 bottles of 30 Tablets 33342-274-10 bottles of 90 Tablets 33342-274-15 bottles of 500 Tablets Febuxostat 80 mg tablets are green, biconvex, teardrop-shaped, film-coated tablets debossed with "M 88" on one side and plain on the other side and supplied as: NDC Number Size 33342-275-07 bottles of 30 Tablets 33342-275-10 bottles of 90 Tablets 33342-275-15 bottles of 500 Tablets Protect from light. Store at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
Abbreviated New Drug Application
FEBUXOSTAT - FEBUXOSTAT TABLETS 40 MG FILM MACLEODS PHARMACEUTICALS LIMITED ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE FEBUXOSTAT TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR FEBUXOSTAT TABLETS. FEBUXOSTAT TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 2009 WARNING: CARDIOVASCULAR DEATH _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ • GOUT PATIENTS WITH ESTABLISHED CARDIOVASCULAR (CV) DISEASE TREATED WITH FEBUXOSTAT TABLETS HAD A HIGHER RATE OF CV DEATH COMPARED TO THOSE TREATED WITH ALLOPURINOL IN A CV OUTCOMES STUDY. (5.1) • CONSIDER THE RISKS AND BENEFITS OF FEBUXOSTAT TABLETS WHEN DECIDING TO PRESCRIBE OR CONTINUE PATIENTS ON FEBUXOSTAT TABLETS. FEBUXOSTAT TABLETS SHOULD ONLY BE USED IN PATIENTS WHO HAVE AN INADEQUATE RESPONSE TO A MAXIMALLY TITRATED DOSE OF ALLOPURINOL, WHO ARE INTOLERANT TO ALLOPURINOL, OR FOR WHOM TREATMENT WITH ALLOPURINOL IS NOT ADVISABLE. (1) INDICATIONS AND USAGE Febuxostat tablets is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. (1) Limitations of Use: (1) Febuxostat tablet is not recommended for the treatment of asymptomatic hyperuricemia. (1) DOSAGE AND ADMINISTRATION Recommended dosage is 40 mg or 80 mg once daily. The recommended starting dosage is 40 mg once daily. For patients who do not achieve a serum uric acid (sUA) less than 6 mg/dL after 2 weeks, the recommended dosage is 80 mg once daily. (2.1) Patients with severe renal impairment: Limit the dosage to 40 mg once daily. (2.2, 8.6) Flare prophylaxis is recommended upon initiation of febuxostat tablets. (2.4) Can be administered without regard to food or antacid use. (2.1) DOSAGE FORMS AND STRENGTHS Tablet: 40 mg, 80 mg. (3) CONTRAINDICATIONS Febuxostat is contraindicated in pat Citiți documentul complet